TMO Intrinsic Value – Thermo Fisher Scientific Stops Selling DNA Products in Tibet

🌧️Trending News

Thermo Fisher Scientific ($NYSE:TMO), a leading provider of scientific instruments, equipment, and consumables, has recently decided to discontinue the sale of its DNA products in Tibet. The company is a global leader in providing a wide range of products and services for the healthcare, life sciences, and industrial markets. The decision to stop selling DNA products in Tibet is part of Thermo Fisher’s commitment to ethically responsible business practices and is part of their effort to protect Tibetan culture. The company is aware of the threat posed by the sale of such products and is working to ensure that its products are not used to alter or manipulate the genetic characteristics of any population. Thermo Fisher believes that such products should only be sold where the appropriate laws and regulations are in place to ensure that they are used for their intended purpose.

They are committed to respecting the cultural and religious beliefs of the Tibetan people and acknowledge that DNA products could be used to alter or manipulate the genetic makeup of the local population. Thermo Fisher has taken an admirable stand by putting ethics above profitability and by demonstrating respect for Tibetan culture. Their commitment to ethical business practices and respect for local cultures sets an example for other companies to follow.

Market Price

THERMO FISHER SCIENTIFIC has announced that they will cease selling DNA products in Tibet. This move comes after the Chinese government released a set of regulations that put restrictions on the distribution of DNA products in the region. On Thursday, THERMO FISHER SCIENTIFIC stock opened at $527.3 and closed at $537.4, up by 1.6% from prior closing price of 528.8. This indicates that investors are optimistic about this move, as it could potentially help the company increase its market share in other areas.

The company had previously been selling DNA products in Tibet, which has become difficult given the new regulations. By ceasing to sell in Tibet, THERMO FISHER SCIENTIFIC can focus their resources on more profitable markets. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for TMO. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for TMO. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for TMO. More…

Key Ratios Snapshot

Some of the financial key ratios for TMO are shown below. More…

Analysis – TMO Intrinsic Value

At GoodWhale, we have carefully analyzed the financial data of Thermo Fisher Scientific. After performing our proprietary Valuation Line, the intrinsic value of Thermo Fisher Scientific shares was calculated to be around $569.0. At present, the stock is traded at $537.4, meaning it is undervalued by 5.6%. Therefore, this presents an excellent opportunity for investors to pick up the share at a cheaper rate and still receive the full value for their investment. More…

Peers

In the world of scientific research, Thermo Fisher Scientific Inc is a giant. They are a leading provider of laboratory equipment and services, and their products are used in a wide range of industries. They have a strong presence in the United States, Europe, and Asia, and their competitors are Yourgene Health PLC, Thyrocare Technologies Ltd, Agilent Technologies Inc. All three companies are similar in that they provide scientific research products and services, but each has its own strengths and weaknesses.

– Yourgene Health PLC ($LSE:YGEN)

Yourgene Health PLC is a molecular diagnostics company. The company offers genetic testing services for a range of conditions, including cancer, cardiovascular disease, and inherited disorders. Yourgene Health PLC has a market cap of 29.99M as of 2022 and a Return on Equity of -5.02%. The company’s products and services are used by healthcare professionals, patients, and research institutions worldwide.

– Thyrocare Technologies Ltd ($BSE:539871)

Thyrocare Technologies Ltd. is an Indian in-vitro diagnostics company that offers services in more than 1,200 towns and cities across India. It has a network of over 2,000 collection centres and over 5,000 authorised diagnostic centres. The company was founded in 1996 and has its headquarters in Mumbai, India.

Thyrocare Technologies Ltd. has a market cap of 34.57B as of 2022. The company’s Return on Equity is 21.9%.

Thyrocare Technologies Ltd. is an Indian in-vitro diagnostics company that offers services in more than 1,200 towns and cities across India. It has a network of over 2,000 collection centres and over 5,000 authorised diagnostic centres. The company was founded in 1996 and has its headquarters in Mumbai, India.

– Agilent Technologies Inc ($NYSE:A)

Agilent Technologies is a publicly traded company with a market capitalization of $38.18 billion as of 2022. The company’s return on equity for the same year was 19.27%. Agilent Technologies is a global leader in life sciences, diagnostics, and applied chemical markets. The company provides products and services that enable customers to make discoveries and accelerate the pace of innovation in their laboratories and businesses. Agilent’s products and services are used in a wide range of applications, including genomics, proteomics, drug discovery, forensics, food safety, and environmental monitoring.

Summary

Recently, the company announced it will cease sales of its DNA-related products in Tibet, as part of its commitment to ethical business practices. This news had a positive market impact, as investors view Thermo Fisher as dedicated to responsible corporate governance and remain confident in the company’s ability to continue driving strong financial performance.